Ipsen’s partner Exelixis announces clinical collaboration with Bristol Myers Squibb for late-stage combination trial in first-line renal cell carcinoma.

Fulfilling our Bold Promise Through External Innovation

It’s time to talk about kidney cancer!

How Ipsen is making patient-centric innovation a reality

Ipsen – Investor Day 2019